convalescent plasma (Henry Ford Health)

Convalescent plasma is a biologic therapy derived from the blood of individuals who have recovered from COVID-19, containing high titers of neutralizing antibodies against the SARS-CoV-2 virus. Henry Ford Health System (HFHS) initiated clinical programs and Phase 2 trials in April 2020 to evaluate the safety and efficacy of this passive immunotherapy in hospitalized patients with severe COVID-19 pneumonia. The therapy involves the intravenous transfusion of ABO-compatible plasma, intended to provide immediate viral neutralization and reduce the severity of respiratory distress. HFHS collaborated with the Mayo Clinic as part of a broader national expanded access program and specific randomized pilot studies to assess the tolerability and efficacy of 200mL transfusions in patients with respiratory disease.

Other names

COVID-19 convalescent plasmaCOVID19 convalescent plasmaCOVID 19 convalescent plasmaCCP